How to Tell If a Peptide Clinic Is Legitimate: A 9-Point Checklist

How can you tell if a peptide clinic is legitimate?

A legitimate peptide clinic has a licensed prescriber evaluate you before any prescription, names its clinicians so you can verify them, dispenses only through a state-licensed 503A pharmacy, an FDA-registered 503B outsourcing facility, or FDA-approved products, promises no results, publishes its prices, requires labs and follow-up, is licensed in your state, states plainly that compounded drugs are not FDA-approved, and backs any LegitScript claim with a verifiable listing.

Why vetting a peptide clinic matters in 2026

Three things changed recently. First, the GLP-1 shortages are over: FDA declared the tirzepatide shortage resolved on December 19, 2024 and semaglutide on February 21, 2025. Compounders may no longer regularly copy the approved products (Mounjaro, Zepbound, Ozempic, Wegovy). A compounded version is permitted only when a prescriber documents a significant clinical difference for an identified patient, so routine compounded GLP-1s fall outside that rule.

Second, the safety reports are real. As of May 31, 2026, FDA had received 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. Those are reports, not proof of cause, but FDA notes some involved hospitalization.

Third, the most marketed “healing” peptides remain off-limits for pharmacies. FDA has published potential significant safety risks for BPC-157, TB-500 (thymosin beta-4 fragment), CJC-1295, AOD-9604, MOTS-c, KPV, Epitalon, and Semax, all eight of which now sit on FDA’s list of bulk substances nominated but withdrawn, having previously been in Category 2. Ipamorelin acetate, GHRP-2, and GHRP-6 (503B), ibutamoren mesylate, sold as MK-677 (503A and 503B), and kisspeptin-10 (503A) still carry explicit Category 2 designations, added in 2022 and 2023.

None of these substances is on FDA’s 503A bulks list, and none meets either of the other two statutory conditions described below, so a clinic that offers them is working outside the compounding pathway FDA describes.

The 9-point legitimacy checklist

1. A licensed prescriber evaluates you before any prescription

Telehealth is fine. Skipping the evaluation is not. A licensed physician, physician associate, or nurse practitioner should review your history, medications, and goals, then decide whether treatment is appropriate. FDA lists “do not require a doctor’s prescription” as its first warning sign of an unsafe online pharmacy.

2. Named clinicians with verifiable credentials

You should be able to learn who prescribes and who reviews the clinic’s medical content, by name and license type, then check them in public license databases. “Our team of doctors,” unnamed, is a gap.

3. A licensed pharmacy or an FDA-approved product, never “research use only”

There are three lawful sources for a prescription peptide or hormone: an FDA-approved product, a state-licensed 503A pharmacy, or an FDA-registered 503B outsourcing facility. Ask which one fills the prescription and where it is licensed or registered. A product sold as “research use only” is neither an approved drug nor a prescription compounded for you, and a consultation does not change that.

4. Any LegitScript certification it claims should check out

LegitScript is a private certifier, not a government agency, and major advertising platforms recognize its certification for healthcare advertisers. A clinic with licensed prescribers, real evaluations, and a licensed dispensing pharmacy can be legitimate without it, so treat it as a claim to verify, not a pass-or-fail test. Its nine published standards include care by a licensed professional before any prescription. Do not trust a seal image: type the clinic’s domain into LegitScript’s public lookup.

5. No guaranteed results and no before-and-after promises

The FTC requires health claims to rest on competent and reliable scientific evidence, and says testimonials reporting results more dramatic than users can generally expect are likely deceptive. A legitimate clinic describes what a therapy was studied for and its side effects, not pounds lost or years reversed.

6. Transparent pricing

Know the full cost before entering payment details: consultation, medication, shipping, follow-up, and billing period. FDA flags “deep discounts or prices that seem too good to be true” as a warning sign.

7. Lab work and follow-up monitoring

Prescription therapies need a baseline and a plan to recheck, and testosterone is the clearest example. The Endocrine Society’s clinical practice guideline recommends diagnosing hypogonadism only in men with symptoms and signs of testosterone deficiency plus unequivocally and consistently low serum testosterone, then evaluating the patient after treatment starts to assess whether he has responded, is having adverse effects, and is following the regimen.

The prostate recommendation is narrower than usually quoted. For hypogonadal men 55 to 69, and for men 40 to 69 at increased risk of prostate cancer, the guideline advises discussing prostate monitoring first, then assessing prostate cancer risk before treatment starts and again 3 to 12 months after starting.

8. Licensed for telehealth in your state

Ask whether the prescriber holds a license in your state, not only the clinic’s home state. LegitScript’s standards require a certified site’s prescribers to be licensed in both the prescriber’s and the patient’s jurisdiction, and require the site to list the states it serves. Controlled substances add a federal layer on top of state licensing: testosterone is Schedule III, and DEA rules also govern telemedicine prescribing of controlled substances, so ask the clinic how it handles that.

9. Clear disclosure that compounded drugs are not FDA-approved

FDA’s language is direct: “Compounded drugs are not FDA-approved. This means the agency does not review their safety, effectiveness or quality before they are marketed.” A clinic dispensing compounded sermorelin, NAD+, or a GLP-1 compounded for an individual patient who meets the clinical-difference standard should say so wherever the product is sold, not only in a footer.

Green flags vs red flags at a glance

Treat any item a clinic will not answer as a reason to keep asking.

Checklist item	Green flag	Red flag
1. Evaluation first	A clinician reviews your history first	Instant approval, or checkout before review
2. Named clinicians	Prescribers and medical reviewer named and licensed	“Our doctors,” no names or licenses
3. Lawful dispensing	State-licensed 503A pharmacy, FDA-registered 503B facility, or FDA-approved product	“Research use only,” or no pharmacy named
4. LegitScript	A claimed certification is current in the lookup	A seal image whose domain is not certified
5. No guarantees	“Was studied for,” “may,” “your provider decides”	“Guaranteed,” or before-and-after photos
6. Transparent pricing	Full price published, with inclusions listed	Hidden fees, or prices far below licensed clinics
7. Labs and follow-up	Baseline labs and a stated recheck schedule	Hormones prescribed with no labs or follow-up
8. Licensed in your state	States served listed; prescriber licensed in yours	No states-served list
9. Compounded disclosure	“Not FDA-approved” on every compounded product	Compounded products called “FDA-approved”

How to verify a clinic’s claims yourself in 15 minutes

1. LegitScript lookup (2 minutes). Enter the clinic’s domain at LegitScript’s certification status page. Certification means the clinic met LegitScript’s standards, not that a treatment will work.
2. Prescriber licenses (6 minutes). DocInfo, from the Federation of State Medical Boards, reports physician licenses and board discipline; NCCPA confirms PA-C certification; Nursys covers nurse practitioners.
3. The dispensing pharmacy (3 minutes). Ask which pharmacy fills prescriptions, then search that state’s board of pharmacy database. FDA’s signs of a safe pharmacy include a U.S. address and phone number, a licensed pharmacist, and state licensure.
4. The product pages (4 minutes). Read the fine print for the compounded disclosure, check any branded product in Drugs@FDA, and watch for guaranteed outcomes or any peptide listed below.

What “compounded” really means, and which peptides fall outside the lawful compounding pathway

Compounding prepares a medication for an individual patient. Section 503A pharmacies are state-licensed, with state boards of pharmacy handling day-to-day oversight. Section 503B outsourcing facilities register with FDA, are subject to current good manufacturing practice requirements, and are inspected by FDA on a risk-based schedule. In both cases the product is not FDA-approved, and FDA has not evaluated it for safety, quality, or efficacy.

A 503A pharmacy may compound with a bulk drug substance only when that substance meets one of three statutory conditions: it complies with an applicable USP or NF monograph if one exists; it is a component of an FDA-approved drug product if no monograph exists; or it appears on FDA’s 503A bulks list. The bulks list is a final rule with no categories. Categories 1, 2, and 3 belong to a separate FDA list of merely nominated substances. Category 1 holds substances still under evaluation, and FDA says it does not intend to act against a compounder using them when its guidance conditions are met. Category 2 raises significant safety concerns; Category 3 covers nominations without adequate support. A drug compounded from a bulk substance meeting none of the three conditions, FDA’s interim policy says, “is not eligible for the exemptions in section 503A.”

Applied to what clinics sell, the test cuts both ways. Nicotinamide adenine dinucleotide (NAD) and enclomiphene citrate both appear in 503A Category 1 on that nominated list, updated May 14, 2026, and neither is FDA-approved. Sermorelin appears nowhere on that list, which is not the same as being off-limits, because a pharmacy may rely on one of the other two conditions instead, so the question to ask is which condition applies. The peptides marketed hardest online meet none of the three.

Peptides outside the lawful pathway as of September 2026

• BPC-157, TB-500, CJC-1295, AOD-9604, MOTS-c, KPV, Epitalon, and Semax: FDA has published potential significant safety risks for all eight, and for BPC-157 and AOD-9604 says it “lacks sufficient information to know whether the drug would cause harm when administered to humans.” None is on the 503A bulks list or in Category 1 or 2 of the nominated list.
• Ipamorelin, ibutamoren (MK-677), GHRP-2, GHRP-6, and kisspeptin-10: these secretagogues carry explicit Category 2 designations on FDA’s safety-risk list: ipamorelin acetate, GHRP-2, and GHRP-6 for 503B outsourcing facilities, ibutamoren mesylate for both 503A and 503B, and kisspeptin-10 for 503A. GHRP-2 and GHRP-6 also sit in 503A Category 3, and none of the five is on the bulks list.
• Compounded semaglutide and tirzepatide: lawful only for an identified patient with a documented clinical difference from the approved product (Ozempic and Wegovy; Mounjaro and Zepbound), never as a routine mass-market offering.

Hormones and peptides with FDA-approved products, and without

Testosterone is the clearest contrast with the peptides above, because FDA-approved testosterone products exist. FDA describes those products as approved only for men who lack or have low testosterone levels in conjunction with an associated medical condition, and no indication for age-related low testosterone alone has been approved, so a clinic that markets testosterone as an anti-aging product is describing something FDA has not approved it for. Testosterone is also a Schedule III controlled substance, so only a licensed provider may prescribe it and a licensed pharmacy dispense it, and a clinic should be able to say how it meets the federal rules for prescribing a controlled substance by telemedicine. See testosterone as a controlled substance and FDA-approved TRT forms.

On the other side of the line sits sermorelin, which is not dispensed under the bulks list at all. Ask which statutory condition the pharmacy relies on for it, and expect the same answer either way: compounded sermorelin is not an FDA-approved product, and FDA has not reviewed its safety, effectiveness, or quality. NAD+ and enclomiphene take the Category 1 route instead, and neither has an FDA-approved product behind it: Drugs@FDA lists no approved NAD+ injection or nasal spray, and enclomiphene is not FDA-approved. Each, where dispensed lawfully, is a compounded prescription FDA has not evaluated for safety, quality, or efficacy.

Red flags that should end the conversation

• No evaluation, or “approval” seconds after you submit a form.
• Products sold as “research use only” or “not for human consumption.”
• Guaranteed results or before-and-after promises as the main pitch.
• A pharmacy you cannot identify, or one outside the United States.
• BPC-157, TB-500, CJC-1295, ipamorelin, ibutamoren (MK-677), GHRP-2, GHRP-6, or kisspeptin-10 listed as available.
• Testosterone prescribed without baseline and follow-up labs.

How Revive approaches peptide therapy

Revive Longevity is a LegitScript-certified telehealth clinic with licensed providers in all 50 states. Every prescription is written by a clinician licensed in your state who reviews your information and decides whether treatment is appropriate. Medications are dispensed by state-licensed compounding pharmacies under section 503A of the Federal Food, Drug, and Cosmetic Act, and the site’s guides and product pages are medically reviewed by Diana Medina, PA-C, a board-certified physician associate. See how Revive works and our FDA July 2026 peptide review.

Pricing is published per 4 weeks: sermorelin at $179 and NAD+ at $179; prices are subject to change and eligibility, and coverage is discussed in is TRT covered by insurance. These are compounded medications: they are not FDA-approved, and the FDA has not evaluated them for safety, quality, or efficacy. Revive does not offer BPC-157, TB-500, ipamorelin, ibutamoren, or any other peptide on FDA’s Category 2 or withdrawn-nomination lists.

Frequently asked questions

What makes a peptide clinic legitimate?

A legitimate clinic has a licensed prescriber evaluate you first, names its clinicians, dispenses only through a state-licensed 503A pharmacy, an FDA-registered 503B outsourcing facility, or FDA-approved products, guarantees no outcomes, publishes prices, requires labs and follow-up, is licensed in your state, and discloses that compounded drugs are not FDA-approved. Any LegitScript certification it claims checks out in LegitScript’s public lookup.

How do I check whether a clinic is LegitScript-certified?

Type the clinic’s domain into LegitScript’s public certification lookup, which reports whether that site holds current certification. LegitScript is a private certifier, not a government agency, and major advertising platforms recognize its certification for healthcare advertisers. A domain that does not come back certified is not automatically a bad actor, but a seal shown without a matching listing is a problem.

Are compounded peptides FDA-approved?

No. FDA states that compounded drugs are not FDA-approved and that the agency does not review their safety, effectiveness, or quality before they are marketed. A legitimate clinic uses only state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities and says so clearly.

Can a legitimate clinic prescribe BPC-157 or TB-500?

Not through a lawful compounding pathway, as of September 2026. FDA’s interim policy says a drug compounded from a bulk substance meeting none of the three statutory conditions is not eligible for the section 503A exemptions. FDA has published potential significant safety risks for both peptides, including immunogenicity. Neither is on FDA’s 503A bulks list or in Category 1 or 2 of FDA’s nominated-substances list, updated May 14, 2026.

Is it legal to get peptide therapy through telehealth?

Yes, when the prescriber is licensed in your state and evaluates you before prescribing. Licensing generally follows the patient’s location, which is why LegitScript’s standards require certified sites to use prescribers licensed in both jurisdictions. The medication must then come from a state-licensed pharmacy, an FDA-registered outsourcing facility, or an FDA-approved product. Controlled substances add a federal layer: testosterone is Schedule III, and telemedicine prescribing of controlled substances is also governed by DEA rules, so ask how the clinic handles that.